{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:30:17Z","timestamp":1782768617815,"version":"3.54.5"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.mcpro.2023.100517","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:35:32Z","timestamp":1676666132000},"page":"100517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-9349","authenticated-orcid":false,"given":"Pedro","family":"Casado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-2274","authenticated-orcid":false,"given":"Pedro R.","family":"Cutillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2023.100517_bib1","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.mcpro.2023.100517_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond\u2014exploring the full potential of targeted therapy for CML","volume":"6","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100517_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nrd4259","article-title":"Kinase inhibitors overachieve in CLL","volume":"13","author":"Garber","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mcpro.2023.100517_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bjh.16356","article-title":"AML through the prism of molecular genetics","volume":"188","author":"Charrot","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.mcpro.2023.100517_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41467-020-14829-5","article-title":"The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants","volume":"11","author":"Rio-Machin","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100517_bib6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/17474086.2014.959923","article-title":"Prognosis and management of acute myeloid leukemia in patients with down syndrome","volume":"7","author":"Caldwell","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.mcpro.2023.100517_bib7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.beha.2014.10.002","article-title":"Fanconi anemia and the development of leukemia","volume":"27","author":"Alter","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.mcpro.2023.100517_bib8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/leu.2015.32","article-title":"Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia","volume":"29","author":"Bochtler","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib9","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2023.100517_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abo0059","article-title":"Targeting AML at the intersection of epigenetics and signaling","volume":"15","author":"Narayan","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.mcpro.2023.100517_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib12","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1073\/pnas.94.10.5320","article-title":"Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice","volume":"94","author":"Bhatia","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100517_bib13","doi-asserted-by":"crossref","first-page":"13576","DOI":"10.1073\/pnas.1301891110","article-title":"Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation","volume":"110","author":"Miraki-Moud","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100517_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5966\/sctm.2013-0166","article-title":"A\u00a0niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms","volume":"3","author":"Griessinger","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.mcpro.2023.100517_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.mcpro.2023.100517_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2023.100517_bib18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25975","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management","volume":"95","author":"Estey","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.mcpro.2023.100517_bib19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5045\/br.2020.S001","article-title":"Classification of acute myeloid leukemia","volume":"55","author":"Hwang","year":"2020","journal-title":"Blood Res."},{"key":"10.1016\/j.mcpro.2023.100517_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","article-title":"Midostaurin: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2023.100517_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","article-title":"Gilteritinib: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2023.100517_bib23","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100517_bib24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/fon-2017-0523","article-title":"The role of IDH mutations in acute myeloid leukemia","volume":"14","author":"Montalban-Bravo","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.mcpro.2023.100517_bib25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-017-0813-2","article-title":"Enasidenib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2023.100517_bib26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2023.100517_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13000-019-0841-1","article-title":"BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia","volume":"14","author":"Zhou","year":"2019","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.mcpro.2023.100517_bib28","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","article-title":"Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid","volume":"13","author":"Andreeff","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.mcpro.2023.100517_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2023.100517_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/14737140.2019.1652095","article-title":"Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia","volume":"19","author":"Shallis","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.mcpro.2023.100517_bib33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41419-018-0647-1","article-title":"Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma","volume":"9","author":"Yao","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mcpro.2023.100517_bib34","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2016-05-718585","article-title":"GLI3 repressor determines hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML","volume":"129","author":"Chaudhry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2023.100517_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-018-1047-7","article-title":"Glasdegib: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2023.100517_bib36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib37","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100517_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.20131128","article-title":"High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias","volume":"211","author":"Shin","year":"2014","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11899-009-0011-8","article-title":"Clinical implications of c-Kit mutations in acute myelogenous leukemia","volume":"4","author":"Malaise","year":"2009","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.mcpro.2023.100517_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1615\/CritRevOncog.v16.i1-2.60","article-title":"TAM receptors in leukemia: expression, signaling, and therapeutic implications","volume":"16","author":"Brandao","year":"2011","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.mcpro.2023.100517_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41419-021-03504-2","article-title":"GLI1 reduces drug sensitivity by regulating cell cycle through PI3K\/AKT\/GSK3\/CDK pathway in acute myeloid leukemia","volume":"12","author":"Zhou","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mcpro.2023.100517_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/13543784.2019.1678583","article-title":"Cyclin-dependent kinase (CDK) 9 and 4\/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach","volume":"28","author":"Lee","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.mcpro.2023.100517_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2023.100517_bib44","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.3390\/ijms21072528","article-title":"CDK6 inhibition: a novel approach in AML management","volume":"21","author":"Uras","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcpro.2023.100517_bib45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature02067","article-title":"Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1","volume":"426","author":"Opferman","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2023.100517_bib46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.mcpro.2023.100517_bib47","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.mcpro.2023.100517_bib48","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100517_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac4380","article-title":"ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies","volume":"9","author":"Ishizawa","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.mcpro.2023.100517_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/13543784.2018.1508448","article-title":"Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia","volume":"27","author":"Chamoun","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.mcpro.2023.100517_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.mcpro.2023.100517_bib52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41420-021-00465-5","article-title":"MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models","volume":"7","author":"Fang","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.mcpro.2023.100517_bib53","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/cancers11111794","article-title":"HDAC inhibitors in acute myeloid leukemia","volume":"11","author":"San Jose-Eneriz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2023.100517_bib54","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/leu.2016.327","article-title":"Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia","volume":"31","author":"Dafflon","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib55","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/cancers11101483","article-title":"Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications","volume":"11","author":"Reyes-Garau","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2023.100517_bib56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mcpro.2023.100517_bib57","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","article-title":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia","volume":"121","author":"Kojima","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2023.100517_bib58","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","article-title":"Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia","volume":"120","author":"Ranganathan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2023.100517_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","article-title":"Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia","volume":"36","author":"de Beauchamp","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib60","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib61","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2023.100517_bib63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.mcpro.2023.100517_bib64","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/bib\/bbx141","article-title":"Proteomics and phosphoproteomics in precision medicine: applications and challenges","volume":"20","author":"Giudice","year":"2019","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.mcpro.2023.100517_bib65","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.mcpro.2023.100517_bib66","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib67","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000606","article-title":"Phosphoproteomic characterization of primary AML samples and relevance for response toward FLT3-inhibitors","volume":"5","author":"Cucchi","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.mcpro.2023.100517_bib68","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100517_bib69","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.celrep.2013.07.018","article-title":"Global proteome analysis of the NCI-60 cell line panel","volume":"4","author":"Gholami","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcpro.2023.100517_bib70","article-title":"Pan-cancer landscape of protein activities identifies drivers of signalling dysregulation and patient survival","author":"Sousa","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.mcpro.2023.100517_bib71","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41587-019-0391-9","article-title":"Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring","volume":"38","author":"Hijazi","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2023.100517_bib72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-0716-1936-0_8","article-title":"Implementation of clinical phosphoproteomics and proteomics for personalized medicine","volume":"2420","author":"Casado","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.mcpro.2023.100517_bib73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/prca.201400104","article-title":"Role of phosphoproteomics in the development of personalized cancer therapies","volume":"9","author":"Cutillas","year":"2015","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.mcpro.2023.100517_bib74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12014-020-09283-w","article-title":"Recent advances in mass spectrometry based clinical proteomics: applications to cancer research","volume":"17","author":"Macklin","year":"2020","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800198","article-title":"Implementation of proteomics in clinical trials","volume":"13","author":"He","year":"2019","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.mcpro.2023.100517_bib76","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nmeth.1333","article-title":"A\u00a0HUPO test sample study reveals common problems in mass spectrometry-based proteomics","volume":"6","author":"Bell","year":"2009","journal-title":"Nat. Methods"},{"key":"10.1016\/j.mcpro.2023.100517_bib77","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41571-018-0135-7","article-title":"Clinical potential of mass spectrometry-based proteogenomics","volume":"16","author":"Zhang","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mcpro.2023.100517_bib78","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41596-018-0006-9","article-title":"Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry","volume":"13","author":"Mertins","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.mcpro.2023.100517_bib79","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ymeth.2011.02.004","article-title":"Characterization of a TiO(2) enrichment method for label-free quantitative phosphoproteomics","volume":"54","author":"Montoya","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.mcpro.2023.100517_bib80","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1074\/mcp.O115.056986","article-title":"A\u00a0biologist's field guide to multiplexed quantitative proteomics","volume":"15","author":"Bakalarski","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib81","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1074\/mcp.O116.059253","article-title":"Omics profiling in precision oncology","volume":"15","author":"Yu","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib82","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1074\/mcp.MR117.000024","article-title":"Methods, tools and current perspectives in proteogenomics","volume":"16","author":"Ruggles","year":"2017","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib83","doi-asserted-by":"crossref","first-page":"100129","DOI":"10.1016\/j.mcpro.2021.100129","article-title":"Decoding post-translational modification crosstalk with proteomics","volume":"20","author":"Leutert","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib84","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12415","article-title":"Development of a bioinformatics platform for analysis of quantitative transcriptomics and proteomics data: the OMnalysis","volume":"9","author":"Tyagi","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.mcpro.2023.100517_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003573","article-title":"Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells","volume":"6","author":"Casado","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.mcpro.2023.100517_bib86","article-title":"Inferring kinase activity from phosphoproteomic data: tool comparison and recent applications","author":"Piersma","year":"2022","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.mcpro.2023.100517_bib87","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20198981","article-title":"INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases","volume":"15","author":"Beekhof","year":"2019","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.mcpro.2023.100517_bib88","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1074\/mcp.RA119.001504","article-title":"Phosphotyrosine-based phosphoproteomics for target identification and drug response prediction in AML cell lines","volume":"19","author":"van Alphen","year":"2020","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib89","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1389201016666150826115626","article-title":"Global cell proteome profiling, phospho-signaling and quantitative proteomics for identification of new biomarkers in acute myeloid leukemia patients","volume":"17","author":"Aasebo","year":"2016","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.mcpro.2023.100517_bib90","doi-asserted-by":"crossref","first-page":"18708","DOI":"10.1073\/pnas.1111840108","article-title":"Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance","volume":"108","author":"Gillet","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2023.100517_bib91","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/pmic.201300448","article-title":"Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines","volume":"14","author":"Aasebo","year":"2014","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib92","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","article-title":"Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells","volume":"32","author":"Casado","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib93","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41375-019-0596-4","article-title":"Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia","volume":"34","author":"Alanazi","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib94","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/cancers12030709","article-title":"Proteome and phosphoproteome changes associated with prognosis in acute myeloid leukemia","volume":"12","author":"Aasebo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2023.100517_bib95","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mcpro.2023.100517_bib96","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.3390\/cancers13092143","article-title":"Proteomic studies of primary acute myeloid leukemia cells derived from patients before and during disease-stabilizing treatment based on all-trans retinoic acid and valproic acid","volume":"13","author":"Hernandez-Valladares","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2023.100517_bib97","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/cancers13133161","article-title":"Global proteomic profiling of pediatric AML: a pilot study","volume":"13","author":"Nguyen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2023.100517_bib98","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","article-title":"The proteogenomic subtypes of acute myeloid leukemia","volume":"40","author":"Jayavelu","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mcpro.2023.100517_bib99","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2023.100517_bib100","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41375-022-01518-z","article-title":"Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML","volume":"36","author":"Caplan","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib101","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12014-022-09367-9","article-title":"Proteomic and phosphoproteomic measurements enhance ability to predict ex\u00a0vivo drug response in AML","volume":"19","author":"Gosline","year":"2022","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib102","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1074\/jbc.M411974200","article-title":"FLT3\/ITD mutation signaling includes suppression of SHP-1","volume":"280","author":"Chen","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2023.100517_bib103","article-title":"Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes","author":"Casado","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.mcpro.2023.100517_bib104","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41467-021-22170-8","article-title":"Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs","volume":"12","author":"Gerdes","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100517_bib105","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1109\/TNNLS.2020.3027314","article-title":"A\u00a0Survey on explainable artificial intelligence (XAI): toward medical XAI","volume":"32","author":"Tjoa","year":"2021","journal-title":"IEEE Trans. Neural Netw. Learn. Syst."},{"key":"10.1016\/j.mcpro.2023.100517_bib106","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41591-022-01961-6","article-title":"Steps to avoid overuse and misuse of machine learning in clinical research","volume":"28","author":"Volovici","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib107","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-020-16735-2","article-title":"A\u00a0cancer drug atlas enables synergistic targeting of independent drug vulnerabilities","volume":"11","author":"Narayan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100517_bib108","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41375-020-01050-y","article-title":"Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia","volume":"35","author":"Murray","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.749","article-title":"Phosphoproteomics profiling reveals a kinase network conferring acute myeloid leukaemia intrinsic chemoresistance and indicates HMGA1 phosphorylation as a potential influencer","volume":"12","author":"Zhu","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.mcpro.2023.100517_bib110","doi-asserted-by":"crossref","first-page":"111177","DOI":"10.1016\/j.celrep.2022.111177","article-title":"Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance","volume":"40","author":"Emdal","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcpro.2023.100517_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abl7989","article-title":"Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment","volume":"15","author":"Pedicona","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.mcpro.2023.100517_bib112","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41375-022-01678-y","article-title":"Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia","volume":"36","author":"Koschade","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2023.100517_bib113","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1074\/mcp.R120.002234","article-title":"Single-cell proteomics: progress and prospects","volume":"19","author":"Kelly","year":"2020","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib114","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1038\/s41467-021-23667-y","article-title":"Quantitative single-cell proteomics as a tool to characterize cellular hierarchies","volume":"12","author":"Schoof","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2023.100517_bib115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jprot.2016.03.049","article-title":"Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows","volume":"145","author":"Aasebo","year":"2016","journal-title":"J.\u00a0Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib116","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1074\/mcp.M113.034751","article-title":"Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cells","volume":"13","author":"Casado","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib117","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/elps.201100170","article-title":"Thermal stabilization of tissues and the preservation of protein phosphorylation states for two-dimensional gel electrophoresis","volume":"32","author":"Smejkal","year":"2011","journal-title":"Electrophoresis"},{"key":"10.1016\/j.mcpro.2023.100517_bib118","article-title":"Clinical applications of mass spectrometry-based proteomics in cancer: where are we?","author":"Boys","year":"2022","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2023.100517_bib119","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1172\/JCI76094","article-title":"Targeting cancer with kinase inhibitors","volume":"125","author":"Gross","year":"2015","journal-title":"J.\u00a0Clin. Invest."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947623000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947623000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:11:29Z","timestamp":1761527489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947623000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1535947623000270"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2023.100517","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2023.100517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100517"}}